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INTRODUCTION
New treatment modalities need economic evaluation in order
to facilitate decisions to better allocate health resources. Health
technology assessment has great value due to enormous variability
in clinical practice; uncertainty about the real impact of some diag-
nostic or therapeutic interventions; rapidity of incorporation and
diffusion of new technologies and incompatibility between new and
old technologies(1).
The economic impact of the most prevalent eye diseases and
their treatment is felt heavily by health services, especially in the
case of glaucoma, the leading cause of irreversible blindness in the
ABSTRACT
Purpose: To assess the resources use, costs and effectiveness of non-penetrating
deep sclerectomy (NPDS).
Methods: A retrospective cohort of NPDS patients was analyzed. Eyes were stratified
according to glaucoma severity into 3 groups: 1 (early), 2 (moderate) and 3 (severe).
NPDS associated resources were based on the frequency of the following variables:
surgical procedure (NPDS), intraoperative mitomycin C (MMC); 5-fluorouracil needling
(5-FU); Nd:YAG laser goniopuncture; new filtering surgery and medications needed
postoperatively. Costs were based on the value and prices of the Brazilian Public
Health System and follow-up period was 5 years. Success rate: percentage of patients
achieving an end-point intraocular pressure <18 mmHg (and least 20% reduction)
without any medications.
Results: Percentage of patients using resources in groups 1, 2 and 3 was, respectively:
92.1%, 88.5% and 93.0% for MMC; 10.5%, 11.5% and 13.3% for 5-FU; 18.4%, 19.7% and
21.9% for goniopuncture and 13.2%, 24.6% and 27.3% for a new surgery. Mean
number of glaucoma medications per patient at the end of follow-up was 0.42 in group
1 and 0.48 and 0.73 in groups 2 and 3, respectively. Mean NPDS direct cost was
US$305.25, US$361.37 and US$390.09 in early, moderate and severe glaucoma, respec-
tively. No differences were found in effectiveness according to glaucoma severity.
Conclusion: There is a trend in the use of resources and costs in NPDS. The more
advanced the glaucoma, the higher the need for resources and the higher the asso-
ciated costs. NPDS effectiveness did not differ among different glaucoma stages.
Keywords: Glaucoma; Primary open-angle glaucoma; Filtering surgery; Costs; Health
care costs
RESUMO
Objetivo: Avaliar a utilização de recursos, os custos e a efetividade da esclerectomia
profunda não penetrante (EPNP).
Métodos: Foi realizado um estudo retrospectivo consecutivo de olhos operados de glau-
coma pela técnica de EPNP. Os olhos foram divididos em três grupos de acordo com a
gravidade do glaucoma: 1 (inicial), 2 (moderado) e 3 (avançado). Os recursos conside-
rados foram baseados nas seguintes variáveis: procedimento cirúrgico (EPNP), uso de
mitomicina C (MMC) intraoperatória, agulhamento com 5-fluoruracil (5-FU), gonio-
puntura com Nd:YAG laser, nova cirurgia filtrante e medicações necessárias no pós-
operatório. O cálculo dos custos foi baseado nos valores exercidos pelo Sistema Único de
Saúde (SUS) no período de 5 anos. O sucesso foi considerado uma pressão intraocular
final <18 mmHg (com pelo menos 20% de redução) sem qualquer medicação anti-
glaucomatosa.
Resultados: A utilização proporcional de recursos nos grupos 1, 2 e 3 foi, respectivamen-
te: 92,1%, 88,5% e 93,0% para MMC; 10,5%, 11,5% e 13,3% para 5-FU; 18,4%, 19,7% e
21,9% para goniopuntura e 13,2%, 24,6% e 27,3% para nova cirurgia filtrante. O custo
direto da EPNP foi de US$305,25 para os glaucomas iniciais; US$361,37 para os mode-
rados e US$390,09 para os avançados. Não foi observada diferença na efetividade da
cirurgia nos três grupos.
Conclusão: Observou-se uma tendência na utilização dos recursos e no custo direto da
EPNP. Quanto mais avançado o glaucoma, maior foi a necessidade de recursos e maiores
foram os custos. A efetividade da EPNP não sofreu influência do estágio evolutivo do
glaucoma.
Descritores: Glaucoma; Glaucoma primário de ângulo aberto; Cirurgia filtrante; Custos;
Custos de cuidados de saúde
world(2). And this trend is increasing, as both incidence and preva-
lence of glaucoma are expected to be higher in the future(3).
Glaucoma-related costs tend to differ according to the severity
of the disease. In the United States, Lee et al. found that these costs
were lower in cases with early visual field damage and higher in
more advanced cases(4). Traverso et al. found this same trend in
Europe(5).
Non-penetrating deep sclerectomy (NPDS) is a filtering glauco-
ma procedure, an alternative to trabeculectomy in patients with
open-angle glaucoma(6,7). Many studies published in the literature
proved its efficacy and safety(8-10).
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It is unknown if the use of resources, the costs and effectiveness
of NPDS are different according to glaucoma stage. The aim of this
study is to compare the resources use, the costs and the effectiveness
of NPDS in a group of operated eyes (stratified in early, moderate
and severe glaucoma) and followed for 5 years.
METHODS
A retrospective study of a consecutive series of eyes undergoing
NPDS from February 2000 to July 2007 was performed. Inclusion
criteria were: history of primary open-angle glaucoma, no previous
glaucoma filtering surgery and at least 5 years of follow-up after
the surgery. If both eyes of a patient were eligible, we chose the
first operated eye for this study. Exclusion criteria were: other types
of glaucoma and previous filtering surgery.
The same surgical team performed all interventions in an outpa-
tient setting.
Surgery was indicated whenever clinical control was not ade-
quate for reaching the target IOP level. NPDS technique was per-
formed as follows(7): Corneal traction with a 8.0 vicryl; fornix-based
conjunctiva and Tenon’s flap; application of mitomycin C (MMC)
(0.2 mg/ml for 3 minutes); superficial scleral flap (5 x 5 mm) with
one-third of the sclera thickness; a triangular-shaped deep scleral
flap (as its dissection goes forward to the limbus, it opens the
Schlemm’s canal); sclerectomy of the deep scleral flap, promoting
a good exposure of the trabeculo-descemetic window; peeling of
the external trabecular membrane with a delicate forceps; repo-
sitioning of the superficial scleral flap with no sutures or implants
and closing of the conjunctival flap with 8.0 vicryl stitches. As the
authors do not use intrascleral implants, they chose not to suture the
superficial scleral flap.
In the beginning of the study, MMC was used in those high-risk
cases for bleb failure, which included: young patients (< 45 years-
old), black race, or previous manipulation of superior conjunctiva,
use of topical medication for more than 5 years prior to the surgery.
However, since 2002 the authors have used it in all cases, indepen-
dently of the presence of factors for bleb failure.
Eyes were stratified, based on the Hoddap, Parrish and Anderson
staging system(11,12), into 3 groups according to glaucoma stage:
early glaucoma (group 1), moderate glaucoma (group 2), and severe
glaucoma (group 3).
Resource use variables were: use of mitomycin C (MMC) intrao-
peratively; number of 5-fluorouracil (5-FU) injections postoperati-
vely; number of Nd:YAG laser goniopunctures postoperatively; num-
ber of reoperations (new filtering procedure) needed and mean
number of anti-glaucoma medications needed postoperatively.
We have calculated the direct costs related to NPDS through the
following variables in a 5-year follow-up:
- Price of NPDS paid by the Brazilian Public National Health
System (SUS). Prices were obtained through the internet in
the SIGTAP table(13);
Price and number of MMC units used intraoperatively;
- Price and number of medications used in the postoperative
period. The authors estimated 1 bottle of 0.3% ciprofloxacin
and 2 bottles of 0.1% dexamethasone per surgical interven-
tion. Another bottle of steroid was also included for gonio-
puncture or when 5-FU injections were needed;
- Price and number of 5-FU injections;
- Price and number of Nd:YAG laser goniopunctures;
- Price and number of surgical reinterventions;
- Price, number and type of glaucoma medications needed after
surgery and for how long this medication was necessary for
up to 5 years of follow-up.
Effectiveness was defined as the mean percentage of intraocu-
lar pressure (IOP) reduction from the preoperative period to the
end of follow-up (5 years). We also calculated the complete success
rate (IOP <18 mmHg and at least 20% reduction from baseline
without any medication) for each one of the groups.
Comparisons among the studied groups were done using
Student T, Anova and Chi-square tests with a significance of 95%.
Statistical analysis was performed using SPSS 13.0 (SPSS Inc.,
Chicago, Illinois, USA).
This study adhered to the tenets of the Declaration of Helsinki.
RESULTS
Two-hundred twenty-seven eyes met the inclusion criteria and
were evaluated in this study. Thirty-eight eyes had early glaucoma
(group 1), 61 eyes had moderate glaucoma (group 2) and 128 eyes
had severe glaucoma (group 3).
Preoperative characteristics (age, race, mean preoperative
number of medications, mean preoperative IOP, mean preopera-
tive cup-to-disc vertical ratio) of the studied groups are presented
in table 1. The number of white patients was 161. The age of the
patients ranged from 31 to 95 years. The mean age of group 3 was
higher than groups 1 and 2 and mean age of group 2 was higher
than group 1.
Postoperative mean number of medications and postoperative
mean IOP showed a statistically significant reduction from preope-
rative values. Comparisons are presented in table 2.
In our study, mean number of MMC use, 5-FU needling, YAG-laser
goniopuncture, surgical reinterventions and number of medica-
tions did not show a statistically significant difference according to
glaucoma stage (refer to table 3). However, there is a trend of a
higher need for resources as glaucoma is more severe, when we
consider mean number of 5-FU needling, YAG-laser goniopuncture,
surgical re-interventions (Figure 1).
Table 4 displays the composition of NPDS costs. Mean cost for
NPDS in severe glaucoma was higher than in moderate and early
glaucoma. There was a slightly trend toward increase in costs
according to glaucoma stage (Figure 2). When resources are consi-
dered, the more advanced the glaucoma, more costly the surgical
procedure (NPDS). Although the difference was not statistically signi-
ficant (p=0.10, ANOVA test), it is marginally significant and may be
clinically relevant from the payers’ perspective.
Effectiveness (mean percentage of IOP reduction from preopera-
tive IOP to final IOP) in groups 1, 2 and 3 are respectively: 42.22%,
39.54% and 48.52%. Complete success rate was 73.7%, 63.9% and
68.5% in groups 1, 2 and 3, respectively (p=0.57).
DISCUSSION
Our results show that there is a slightly trend in NPDS costs
according to glaucoma stage (p=0.10, a weak statistically signifi-
Table 1. Preoperative characteristics of the studied population,
according to glaucoma stage
Glaucoma stage*
Early Moderate Severe
Characteristics (n=38)  (n=61)  (n=128) p value
Age (years) 56.97 63.03 66.70 <0.0001
Race Whites 16.8% 26.1% 57.1% <0.9100
Non-whites** 16.7% 28.8% 54.5%
Mean number of medications 02.61 02.75 02.79 <0.2900
Mean IOP (mmHg) 23.92 22.13 24.63 <0.0000
Mean C/D 00.52 00.68 00.85 <0.0001
IOP= intraocular pressure; C/D= vertical cup-to-disc ratio; p= statistical significance
(Anova and Chi-square)
*= Hoddap, Parrish and Anderson staging system(11)
**= Non-whites included blacks and mixed blacks and whites
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cance). The more advanced the glaucoma, the higher are the asso-
ciated costs. Clinically, NPDS achieved the same success rate in all
glaucoma stages. Therefore, in more severe glaucomas this higher
use of resources and costs resulted in an effective and comparable
IOP control up to 5 years of follow-up.
The studied population was homogeneous in race and mean
number of medications prior to surgery. Those two were potential
confounding variables, as they might lead to differences in wound
healing response(14,15) and, therefore, the number of resources used,
mainly MMC and 5-FU injections.
Differences among the studied groups (early, moderate and
severe glaucoma) were found in age, mean preoperative IOP and
cup-to-disc vertical ratio. Age could influence the use of resources,
as the younger the patient, the more postoperative fibroblastic
reaction is expected(14,16). However, this effect was not observed.
According to our results, early glaucoma patients tended to use fewer
resources. This might be explained by the very similar mean ages
in the studied groups (56.97; 63.03 and 66.70 years, respectively in
early, moderate and severe glaucoma). This difference was statisti-
cally, but not clinically significant.
In spite of some criticism concerning Hoddap, Parrish and An-
derson glaucoma staging system(12), we chose to use it because it is
the most spread and easy to apply one.
Significant reduction from baseline to the end of follow-up was
observed in both mean number of medications and IOP. Mean
percentage of IOP reduction and success rate was not statistically
different among groups. Complete success rate was 73.7%, 63.9%
and 68.5% in early, moderate and severe glaucoma, respectively
(p=0.57). Our results are comparable to the published literature(6-10).
Although not statistically significant, early glaucoma showed a
fewer need for resources use, in order to achieve the same success
rate, than moderate and severe glaucoma. Severe glaucoma used
proportionally more resources than early and moderate glaucoma.
We observed a trend in all resources (5-FU, Nd:YAG laser goniopunc-
ture, need for a new glaucoma surgical procedure and mean num-
ber of medications), except one (MMC). The percentage of patients
needing a 5-FU needling in the postoperative period was 10.5% in
early glaucoma, 11.5% in moderate glaucoma and 13.3% in severe
glaucoma. The percentage of patients that underwent a gonio-
puncture was 18.4%, 19.7% and 21.9% in early, moderate and
severe glaucoma, respectively. The need for a new glaucoma sur-
gery does also differ according to glaucoma stage. In early glauco-
ma, 13.2% of patients needed a new filtering procedure. In mode-
rate and severe glaucoma, this number was up to 24.6% and 27.3%,
respectively. Despite a significant reduction in the mean number
of medications in all groups from baseline, we observed that the
more advanced the glaucoma, the higher the mean number of
glaucoma medications in the postoperative period.
This trend was not observed for MMC. This was because the use
of MMC is based on the preoperative estimation of risk for failure
according to several parameters, such as race, age, number of preo-
perative glaucoma medications, prior ophthalmic surgery, among
others(14).
Although none of the resources comparisons among glaucoma
stages obtained statistical significance, from the economic pers-
pective it can cause a great deal of influence. The Brazilian Public
Health System (SUS) pays the amount of US$ 147.27 for each glauco-
ma surgery(13), however the total direct surgical cost when resour-
Table 2. Pre and postoperative comparisons of mean number of medications per patient, mean intraocular pressure and mean
cup-to-disc ratio, according to glaucoma stage
Comparisons from baseline to the end of follow-up
Glaucoma Number of medications IOP (mmHg) C/D
stage* Baseline Final  p value Baseline Final  p value Baseline Final  p value
Early 2.61 0.42 <0.0001 23.92 13.82 <0.0001 0.52 0.52 0.16
Moderate 2.75 0.48 <0.0001 22.13 13.48 <0.0001 0.68 0.68 0.32
Severe 2.79 0.73 <0.0001 24.63 12.64 <0.0001 0.85 0.85 0.04
IOP= intraocular pressure; C/D= vertical cup-to-disc ratio; p= statistical significance (Student T test for paired samples)
*= Hoddap, Parrish and Anderson staging system(11)
Table 3. Use of resources according to glaucoma stage
Glaucoma stage*
Resources Early Moderate Severe p value
MMC - proportion of patients 35/38 (92.1%) 54/61 (88.5%) 119/128 (93.0%) 0.58
5-FU needling - proportion of patients 04/38 (10.5%) 07/61 (11.5%) 017/128 (13.3%) 0.87
Goniopuncture - proportion of patients 07/38 (18.4%) 12/61 (19.7%) 028/128 (21.9%) 0.87
New surgery - proportion of patients 05/38 (13.2%) 15/61 (24.6%) 035/128 (27.3%) 0.20
Mean number of medications 0.42 0.48 0.73 0.08
MMC= mitomycin C used intraoperatively; 5-FU= 5 fluorouracil; p= statistical significance (Anova and Chi-square)
*= Hoddap, Parrish and Anderson staging system(11)
Figure 1. Percentage of 5-FU injections, goniopuncture and new surgery according to
glaucoma stage.
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Table 4. Non-penetrating deep sclerectomy resources use and direct costs according to glaucoma stage
Glaucoma stage*
NPDS cost Early Moderate Severe
composition Unit cost (US$) Units Total cost (US$) Units Total cost (US$) Units Total cost (US$)
NPDS 147.27 38 5,596.26 61 8,983.47 128 18,850.56
Resources MMC 030.10 35 1,053.50 54 1,625.40 119 03,581.90
5-FU 014.02 04 0,056.08 07 00,98.14 017 00,238.34
Goniopuncture 015.91 07 0,111.37 12 0,190.92 028 00,445.48
New surgery 147.27 05 ,0736.35 15 2,209.05 035 05,154.45
Medications § NA NA 3,004.31 NA 7,304.40 NA 18,204.52
Total cost NA NA 11,599.32 NA 22,043.59 NA 49,931.25
Total cost per eye NA NA ,0305.25 NA 0,361.37 NA 00,390.09
§= medications costs included all necessary antibiotics, steroids and any hypotensive agents in the postoperative period up to 5 years of follow-up; NPDS= non-penetrating deep
sclerectomy; MMC= mitomycin C used intraoperatively; 5-FU= 5 fluorouracil needling; NA= not applicable
* Hoddap, Parrish and Anderson staging system(11)
Figure 2. Trend in NPDS direct costs per patient according to glaucoma stage (p=0.10).
ces costs are incorporated is different. Mean total cost per opera-
ted eye in the early glaucoma group was US$ 305.25. In moderate
and severe glaucomas, this cost was US$ 361.37 and US$ 390.09,
respectively (p=0.10).
Performing NPDS in early glaucoma can generate cost savings
of approximately US$ 85.00 per patient compared to severe glauco-
ma, with a much lesser need of postoperative reinterventions (5-FU
needling [10.5% versus 13.3%], goniopuncture [18.4% versus 21.9%]
and new filtering procedure [13.2% versus 27.3%]). It is expected
that the lesser the need for postoperative reinterventions, the
better the quality of life of patients.
Glaucoma direct costs have an enormous impact on health care,
because it includes: chronic use of medications, surgical procedu-
res, medical visits and frequent exams(5). Glaucoma chargers are res-
ponsible for up to 12% of all medical expenses in glaucoma pa-
tients(17). Medications contribute with a significant proportion of
glaucoma related direct costs(4,5). Rylander and Vold estimated the
annual costs with a single medication in the United States. It varied
from US$ 150.81 to US$ 873.98(18). If a patient needs more than one
medication, which is not unusual(19,20), theses costs are even higher.
In our current world’s ever-limiting health care budget, econo-
mic assessment of different treatment options are very useful and
may help decision makers to advice the most suitable one for each
environment. Brazilian’s Health Care System (SUS) cannot afford to
keep every glaucoma patient under chronic use of medications.
Besides some problems associated with this chronic regimen (per-
sistence, adherence, side effects, etc)(21,22), the costs of such strategy
are extremely high. From the public health perspective, a cost-effec-
tive analysis of medications versus surgery can help health care
policy and decision makers decide the most suitable treatment. We
are currently working on a project on the cost-effectiveness analysis
of different glaucoma treatments in Brazil.
Costs in glaucoma vary a lot according to glaucoma stage(4,5). Lee
et al. found that an early glaucoma costs in average US$ 623.00 and
an end-stage disease can achieve values of US$ 2,511.00(4). Compa-
rable results were obtained by Traverso et al., assessing glaucoma
costs in Europe (5). Surgical costs comparisons to these two studies
are difficult to perform, as in these previous studies, global direct
costs were assessed (including medications, consultations, exams
and surgeries by various techniques) and in our study we only focused
on NPDS direct costs.
There is evidence that glaucoma medications are the major res-
ponsible for the total cost in every stage of glaucoma(4,5). That is why
it is important that, from the economic point of view, surgery
should be considered earlier in the glaucoma treatment. When we
look only at the surgery-related costs, as we did in our study, we
see that costs are lower in the earlier stages of the disease.
NPDS has some advantages over trabeculectomy that can en-
courage physicians to early indicate surgery. It has the same ability to
control IOP, as demonstrated in several studies around the world(8,9).
At the same time, it shows fewer complications, making it a safer
procedure(6-10). When performed in early glaucoma cases, NPDS can
also be a cost saving procedure.
In summary, NPDS comparative effectiveness is similar in all
severity stages of glaucoma. Conversely, there is a trend toward the
use of resources and associated costs in NPDS. A more advanced
glaucoma tends to need more resources and postoperative
reinterventions than an earlier one. Accordingly, NPDS associated
direct costs are significantly higher in more severe glaucoma.
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